Yoel Kessler

Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study

Messoud Ashina, Joshua M. Cohen, Maja Galić et al. · The Journal of Headache and Pain · 2021 · 43 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting System

Stephen D. Silberstein, Shoshana Reshef, Joshua M. Cohen et al. · Advances in Therapy · 2022 · 41 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

A Pharmacokinetic Bioequivalence Study of Fremanezumab Administered Subcutaneously Using an Autoinjector and a Prefilled Syringe

Irina Cherniakov, Orit Cohen‐Barak, Ryan Tiver et al. · Clinical Pharmacology in Drug Development · 2021 · 13 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Dose selection for fremanezumab (AJOVY) phase 3 pediatric migraine studies using pharmacokinetic data from a pediatric phase 1 study and a population pharmacokinetic modeling and simulation approach

Orit Cohen‐Barak, Andrijana Radivojevic, Aksana K. Jones et al. · Cephalalgia · 2021 · 12 citations

Pharmacy, Pharmacokinetics, Pharmacology +16

Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies

Hans‐Christoph Diener, Peter McAllister, Tim Jürgens et al. · Cephalalgia · 2022 · 12 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +16